Antilipemic Agents - Therapeutic use
Research News and Information

Monday, November 23, 2009

Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study.

Nov 2009 OBJECTIVES: Our aim was to determine the effects of high-dose (2 g) nicotinic acid (NA) on progression of atherosclerosis and measures of vascular function. BACKGROUND: NA raises high-density lipoprotein cholesterol (HDL-C) and reduces low-density ... Read more...

Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels.

24 Oct 2009 BACKGROUND: The role of high-density lipoprotein cholesterol (HDL-C) as a therapeutic target to prevent cardiovascular (CV) events remains unclear. We examined data from the Framingham Offspring Study from 1975 through 2003 to determine whether ... Read more...

2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations.

29 Sep 2009 The present article represents the 2009 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the ... Read more...

Latest indexed articles for 'Antilipemic Agents - Therapeutic use'

These are the very latest articles for this heading:

• Assessing niacin as an atherosclerosis therapeutic agent valuable insights provided by high-resolution vascular magnetic resonance imaging. Nov 2009
• Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. Nov 2009
• ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. 24 Oct 2009
• Evaluating the incremental benefits of raising high-density lipoprotein cholesterol levels during lipid therapy after adjustment for the reductions in other blood lipid levels. 24 Oct 2009
• Lipoprotein(a) measurement and determining risk of myocardial infarction. 19 Oct 2009
• 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. 29 Sep 2009
• Lipid lowering and aortic valve disease. 30 Aug 2009
• ApoB versus non-HDL-C: what to do when they disagree. 30 Aug 2009
• Lipid-lowering drugs and risk for cancer. 30 Aug 2009
• Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. 30 Aug 2009
• Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies. 30 Aug 2009
• Circumventing glucocorticoid-mediated hyperinsulinemia via the activation of PPARalpha. 13 Aug 2009
• Association between prescription burden and medication adherence in patients initiating antihypertensive and lipid-lowering therapy. 13 Aug 2009
• Letter by barrios et Al regarding article, "heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial". 2 Aug 2009
• Quality of care for acute coronary syndrome patients with known atherosclerotic disease: results from the Get With the Guidelines Program. Aug 2009
• Effects of sour tea (Hibiscus sabdariffa) on lipid profile and lipoproteins in patients with type II diabetes. 30 Jul 2009
• Factors associated with recurrent coronary events among patients with cardiovascular disease. 30 Jul 2009
• Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. 30 Jul 2009
• Lipid management in clinical practice. 30 Jul 2009
• Targets for LDL-lowering therapy. 30 Jul 2009

See a longer list of these articles.

Technical information about 'Antilipemic Agents'

Definition: Substances used to treat HYPERLIPIDEMIAS.

Registry Number: 0

Descriptor UI: D000960

Alternative terms: Antilipemic Agents; Agents, Antilipemic; Antihyperlipidemics; Antihyperlipemics; Antilipemics; Antilipemic Drugs; Drugs, Antilipemic; Hypolipidemic Agents; Agents, Hypolipidemic;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D27.505.519.186.071; D27.505.954.230;

History Note: 72(66)